Elite Pharmaceuticals appoints Mark Pellegrino as CFO effective May 1, 2023

ELITE PHARMACEUTICALS INC /NV/

Mark Pellegrino appointed CFO, replacing Robert Chen, effective May 1, 2023.
Annual base salary of $230,000; eligible for 1.5M stock options vesting over 3 years.
Pellegrino has 30+ years of life sciences finance experience, most recently consultant at Barbera & Barbera.
Stock option strike price set at closing price on first day of employment (ELTP).

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Chen

Chief Financial Officer

ELTP · ELITE PHARMACEUTICALS INC /NV/

Effective: 2023-05-01
Successor: Mark Pellegrino
Filed: May 3, 2023, 7:59 PM ET

On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.

Appointed

Mark Pellegrino

Chief Financial Officer

ELTP · ELITE PHARMACEUTICALS INC /NV/

Effective: 2023-05-01
Filed: May 3, 2023, 7:59 PM ET

On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.85

Robert Chen departed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.

Action: departed
Role: Chief Financial Officer

Exact text from the filing

On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Pellegrino was appointed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.

View on SEC.gov

ELITE PHARMACEUTICALS INC /NV/ filing history →

Source: SEC EDGAR

accession 0001493152-23-015304

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.